TheraRadar
Data updated: Jun 28, 2026

CIPROFLOXACIN AND DEXAMETHASONE (ciprofloxacin) · UPSHER SMITH LABS

Corticosteroid Hormone Receptor Agonists
Infectious Disease Approved 2020-08-10

This otic suspension is a combination of a fluoroquinolone antibacterial and a corticosteroid. It is indicated for the treatment of acute otitis media (AOM) in pediatric patients (6 months and older) with tympanostomy tubes, as well as acute otitis externa (AOE) in pediatric (6 months and older), adult, and elderly patients. The combination addresses susceptible bacterial infections while simultaneously reducing the associated inflammatory response.

Source: FDA Label • Corticosteroid

How CIPROFLOXACIN AND DEXAMETHASONE Works

Ciprofloxacin is a fluoroquinolone antibacterial that targets susceptible bacteria. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines. This results in decreased edema, fibrin deposition, capillary leakage, and reduced migration of inflammatory cells to the site of infection.

Source: FDA Label
5
Indications
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-08-10
Routes
OTIC
Dosage Forms
SUSPENSION/DROPS

CIPROFLOXACIN AND DEXAMETHASONE Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2020 to 2026
Jan 2026 ORIGINAL
Update
Jul 2025 SUPPL
Label · Labeling
Mar 2024 ORIGINAL
Update

What CIPROFLOXACIN AND DEXAMETHASONE Treats

2 indications

CIPROFLOXACIN AND DEXAMETHASONE is approved for 2 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

CIPROFLOXACIN AND DEXAMETHASONE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 6 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CIPROFLOXACIN AND DEXAMETHASONE

3 of 11

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AUGMENTIN ES-600
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
AZITHROMYCIN
AZITHROMYCIN
1 shared
NOVEL LABS INC
Shared indications:
BACTRIM
SULFAMETHOXAZOLE
1 shared
Sun Pharma
Shared indications:
📋

Clinical Trial Registry

76 trials
Trial Sponsor ID Phase Status Title
NCT04791579 Pro00108452 Ph 2 recruiting Antibiotic Prophylaxis for Neurogenic Bladder Botox
NCT01243437 results posted CDC-NCEZID-5859 Ph 2 completed A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
NCT04948463 ELSA-FN 74690 Ph 4 completed Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT05294588 21-0498 DMID 21-0018, U01AI162457-01 Ph 2 completed Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
NCT05274672 022-046 Ph 4 withdrawn Role of Prophylactic Postoperative Antibiotics in HoLEP
NCT03012360 TAVeM2 2015_66 2016-000735-41 Ph 4 terminated Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
NCT03850379 results posted 12124) Ph 2 completed Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
NCT05846399 CATBITE 2092043 Ph 4 recruiting CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
NCT04523987 PA02/07/18 Ph 1 active not recruiting A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
NCT05844735 PDY16917 U1111-1255-5054 Ph 1 completed A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
NCT04444440 Pro00101838 Ph 4 recruiting Antibiotic Prophylaxis for Bladder Botox
NCT07150065 107 Ph 2 completed Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever
NCT07016165 KE/FK/0517/EC/2025 Ph 4 recruiting Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07028424 PANORAMIX PANORAMIX G-116 PRODIGE 105 Ph 2 not yet recruiting PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
NCT01753115 results posted EBS.AVA.009 Ph 2 completed Ciprofloxacin BioThrax Co-Administration Study
NCT03692715 APPEAL CLUE Ph 4 completed Antibiotic Prophylaxis Before Shock Wave Lithotripsy
NCT04110340 IMASOY 45-18 Ph 3 completed Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
NCT03862170 BRP30 AA-HCLM-14-033 Ph 3 terminated Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
NCT06709196 REINFORCE 2024-514312-27-00 2024-514312-27-00 Ph 4 recruiting Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
NCT05462496 STUDY-21-01814 Ph 2 recruiting Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT02765256 Holiday results posted 823635 Ph 2 completed Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
NCT02598362 2014-004638-24 Ph 4 completed Pharmacokinetics of Ciprofloxacin in Pediatric Patients
NCT02620007 TEOREM P140503 Ph 2 terminated Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
NCT04147260 results posted 1407-0037 Ph 1 completed Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
NCT03854929 CIPAZ 26EN Ph 4 completed Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
NCT03262142 Target-ABC coptrin2 Ph 4 terminated Targeted AntiBiotics for Chronic Pulmonary Diseases
NCT03228108 pro-SWAP pro-SWAP104622 Ph 4 completed Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
NCT04698057 ACACIA ACACIA Ph 3 withdrawn Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.
NCT02790138 EARNEST results posted Vedolizumab-4004 U1111-1171-0918, 2015-003472-78 Ph 4 completed A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
NCT03476317 Holiday results posted 17-014343 5K23DK109136-02 Ph 2 completed Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
NCT04870138 results posted 09-0106 LptA Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
NCT03177720 ELF Cipro Ph 1 completed Evaluation of Innovative Tools in Development of Antibiotics
NCT00654108 07-0052 Ph 1 completed Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
NCT00832286 07-0053 Ph 1 completed Longitudinal Study of the Human Intestinal Microbiome
NCT03840811 results posted 09-0106 Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae
NCT02300220 results posted 14IC2031 2012-002198-72 Ph 3 completed Targeted Retreatment of COPD Exacerbations
NCT03354598 results posted IT001-301 Ph 3 completed Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
NCT03357614 results posted IT001-302 Ph 3 completed Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
NCT03358576 results posted IT001-303 Ph 3 completed Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
NCT00992329 HP-00043432 HHSF223200810030C Ph 1 completed Impact of Formulation on Ciprofloxacin Oral Absorption
NCT02816112 REaCT-TC2 OTT 16-03 Ph 4 completed Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
NCT01888822 MarPic63 Ph 4 terminated Antibiotic Prophylaxis in Laparoscopic Cholecystectomy
NCT01789203 results posted Pro00007510 IRB0612-0114 Ph 4 completed Ciprofloxacin for Prevention of BK Infection
NCT01783106 APRiCCOT Royal_Liverpool 2008-001137-99 Ph 2 completed Antibiotics and Hydroxychloroquine in Crohn's
NCT03366207 results posted IT004-401 Ph 4 completed Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
NCT03431675 Cipro chemoprophylaxis 2018 Ph 4 withdrawn Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
NCT02068846 results posted 12-0036 1R21DE023046-01A1 Ph 3 completed BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
NCT01659866 results posted STU00059558 EAM-237 Ph 4 completed Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01505634 results posted 7655-003 2011-005707-32, MK-7655-003 Ph 2 completed Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
NCT01952444 results posted AH110 Ph 1 completed Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Showing 50 of 76 trials

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CIPROFLOXACIN AND DEXAMETHASONE FDA Label Details

Indications & Usage

Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis , and Pseudomonas aeruginosa. Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . Ciprofloxaci...

Track CIPROFLOXACIN AND DEXAMETHASONE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.